InvestorsHub Logo
Followers 2
Posts 485
Boards Moderated 0
Alias Born 03/22/2012

Re: None

Monday, 02/04/2019 10:24:21 PM

Monday, February 04, 2019 10:24:21 PM

Post# of 27409
Let me get this right. Spectral Medical is seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock,by utilizing Toraymyxin to remove endotoxins, which can cause sepsis, from the bloodstream. CytoSorb-XL is a new, state-of-the-art porous polymer bead technology that combines lipopolysaccharide (LPS) endotoxin removal with the robust cytokine, toxin, and inflammatory mediator reduction achieved by CytoSorb. CytoSorb-XL is expected to eliminate the need for stand-alone endotoxin specific filters by offering superior performance in the removal of not just endotoxin, but a much broader array of inflammatory mediators that drive uncontrolled deadly inflammation, organ failure, and death in sepsis. This is from Cytosorb's website, so shouldn't Cytosorb XL put Spectral out of business when it comes online?

https://cytosorbents.com/cytosorbents-advances-war-on-sepsis-with-development-of-cytosorb-xl/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News